Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Pharmacol., 13 November 2025

Sec. Drugs Outcomes Research and Policies

Volume 16 - 2025 | https://doi.org/10.3389/fphar.2025.1735585

Correction: Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma

This article is a correction to:

  1. Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma

    1. Read original article
Yan Zhu&#x;Yan Zhu1†Cheng He&#x;Cheng He1†Shi-Chao CaoShi-Chao Cao1Hui-Jun LiHui-Jun Li2Ru-Xue CaiRu-Xue Cai3Zhao-Jun BaiZhao-Jun Bai4Tong-Xia Xia, Tong-Xia Xia1,5*
  • 1Department of Pharmacy, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China
  • 2Department of Pharmacy, Zunyi Bozhou District People’s Hospital, Zunyi, Guizhou, China
  • 3Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd., Economic and Technological Development District, Guiyang, Guizhou, China
  • 4Guangxi Shenli Pharmaceutical Co., Ltd., Yulin, Guangxi, China
  • 5School of Nursing, Zunyi Medical University, Zunyi, Guizhou, China

A Correction on
Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma

by Zhu Y, He C, Cao S-C, Li H-J, Cai R-X, Bai Z-J and Xia T-X (2025). Front. Pharmacol. 16:1556304. doi: 10.3389/fphar.2025.1556304

Affiliation 1 Department of Pharmacy, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China was omitted for author Tong-Xia Xia. This affiliation has now been added for author Tong-Xia Xia.

The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: cost-effectiveness analysis, advanced hepatocellular carcinoma, cabozantinib, atezolizumab, sorafenib

Citation: Zhu Y, He C, Cao S-C, Li H-J, Cai R-X, Bai Z-J and Xia T-X (2025) Correction: Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma. Front. Pharmacol. 16:1735585. doi: 10.3389/fphar.2025.1735585

Received: 30 October 2025; Accepted: 31 October 2025;
Published: 13 November 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Zhu, He, Cao, Li, Cai, Bai and Xia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Tong-Xia Xia, eHR4MDkyNUAxNjMuY29t

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.